UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 8, 2015

 

ABBVIE INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-35565

 

32-0375147

(State or other Jurisdiction

 

(Commission File Number)

 

(IRS Employer

of Incorporation)

 

 

 

Identification No.)

 

 

1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code:  (847) 932-7900

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR    240.14d-2(b))

 

o                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 5.07.  Submission of Matters to a Vote of Security Holders.

 

AbbVie Inc. (“AbbVie”) held its Annual Meeting of Stockholders on May 8, 2015.  The following is a summary of the matters voted on at that meeting.

 

(1)                                 The stockholders elected AbbVie’s Class III Directors with terms expiring in 2018, as follows:

 

Name 

 

For

 

Withheld

 

Broker Non-Votes

 

Roxanne S. Austin

 

1,016,745,497

 

118,346,407

 

230,005,019

 

Richard A. Gonzalez

 

1,085,992,401

 

49,099,503

 

230,005,019

 

Glenn F. Tilton

 

1,114,111,201

 

20,980,703

 

230,005,019

 

 

(2)                                 The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2015, as follows:

 

For

 

Against

 

Abstain

 

1,331,520,648

 

30,658,983

 

2,917,292

 

 

(3)                                 The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers listed in the proxy statement for the 2015 annual meeting, as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

1,075,816,444

 

51,054,382

 

8,221,078

 

230,005,019

 

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ABBVIE INC.

 

 

 

 

 

Date:   May 11, 2015

By:

/s/ Laura J. Schumacher

 

 

Laura J. Schumacher

 

 

Executive Vice President, Business Development, External Affairs and General Counsel

 

3